Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy

被引：0
|
作者：
Prithviraj, Prashanth
McArthur, Grant A.
Atkinson, Victoria
Parente, Phillip
Andrews, Miles Cameron
Parakh, Sagun
Cebon, Jonathan S.
Klein, Oliver
机构：
[1] Austin Hlth, Med Oncol Unit, Heidelberg, Vic, Australia
[2] Peter MacCallum Canc Ctr, East Melbourne, Australia
[3] Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia
[4] Monash Univ, Box Hill Hosp, Eastern Hlth Clin Sch, Melbourne, Vic 3004, Australia
[5] Austin Hosp, Heidelberg, Vic, Australia
[6] Austin Hosp, Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9059
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
    Seidel, Judith A.
    Otsuka, Atsushi
    Kabashima, Kenji
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [32] Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma
    Maker, AV
    Yang, JC
    Sherry, RM
    Topalian, SL
    Kannula, US
    Royal, RE
    Hughes, M
    Yellin, MJ
    Haworth, LR
    Levy, C
    Allen, T
    Mavroukakis, SA
    Attia, P
    Rosenberg, SA
    JOURNAL OF IMMUNOTHERAPY, 2006, 29 (04) : 455 - 463
  • [33] Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma
    Li, Mengqian
    LANCET ONCOLOGY, 2021, 22 (08): : E342 - E342
  • [34] Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma
    Campbell, Katie M.
    Amouzgar, Meelad
    Pfeiffer, Shannon M.
    Howes, Timothy R.
    Medina, Egmidio
    Travers, Michael
    Steiner, Gabriela
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Larkin, James
    Hodi, F. Stephen
    Boffo, Silvia
    Salvador, Lisa
    Tenney, Daniel
    Tang, Tracy
    Thompson, Marshall A.
    Spencer, Christine N.
    Wells, Daniel K.
    Ribas, Antoni
    CANCER CELL, 2023, 41 (04) : 791 - +
  • [35] Intratumoral CD16± Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
    Lee, Hansol
    Ferguson, Angela L.
    Quek, Camelia
    Vergara, Ismael A.
    daSilva, Ines Pires
    Allen, Ruth
    Gide, Tuba Nur
    Conway, Jordan W.
    Koufariotis, Lambros T.
    Hayward, Nicholas K.
    Waddell, Nicola
    Carlino, Matteo S.
    Menzies, Alexander M.
    Saw, Robyn P. M.
    Shklovskaya, Elena
    Rizos, Helen
    Lo, Serigne
    Scolyer, Richard A.
    V. Long, Georgina
    Palendira, Umaimaintha
    Wilmott, James S.
    CLINICAL CANCER RESEARCH, 2023, 29 (13) : 2513 - 2524
  • [36] ANTI-CTLA-4 ANTIBODY THERAPY (IPILIMUMAB) INDUCED LUPUS-LIKE SKIN MANIFESTATIONS IN A METASTATIC MELANOMA PATIENT
    Calder, K.
    Armstrong, C.
    Hiatt, K.
    Smoller, B.
    Cheung, W.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2011, 38 (01) : 93 - 93
  • [37] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
    Gauci, Marie-Lea
    Boudou, Philippe
    Baroudjian, Barouyr
    Vidal-Trecan, Tiphaine
    Da Meda, Laetitia
    Madelaine-Chambrin, Isabelle
    Basset-Seguin, Nicole
    Bagot, Martine
    Pages, Cecile
    Mourah, Samia
    Resche-Rigon, Matthieu
    Pinel, Sylvine
    Sassier, Marion
    Rouby, Franck
    Eftekhari, Pirayeh
    Lebbe, Celeste
    Gautier, Jean-Francois
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (08) : 1197 - 1208
  • [38] Real-world efficacy and safety data of anti-PD-1 plus anti-CTLA-4 combination therapy in Chinese patients with advanced melanoma.
    Wen, Xizhi
    Zhang, Xiaoshi
    Ding, Ya
    Li, Dandan
    Li, Jingjing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
    Marie-Léa Gauci
    Philippe Boudou
    Barouyr Baroudjian
    Tiphaine Vidal-Trecan
    Laetitia Da Meda
    Isabelle Madelaine-Chambrin
    Nicole Basset-Seguin
    Martine Bagot
    Cécile Pages
    Samia Mourah
    Matthieu Resche-Rigon
    Sylvine Pinel
    Marion Sassier
    Franck Rouby
    Pirayeh Eftekhari
    Céleste Lebbé
    Jean-François Gautier
    Cancer Immunology, Immunotherapy, 2018, 67 : 1197 - 1208
  • [40] Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients
    Nakamura, Yasuhiro
    Namikawa, Kenjiro
    Kiniwa, Yukiko
    Kato, Hiroshi
    Yamasaki, Osamu
    Yoshikawa, Shusuke
    Maekawa, Takeo
    Matsushita, Shigeto
    Takenouchi, Tatsuya
    Inozume, Takashi
    Nakai, Yasuo
    Fukushima, Satoshi
    Saito, Shintaro
    Otsuka, Atsushi
    Fujimoto, Noriki
    Isei, Taiki
    Baba, Natsuki
    Matsuya, Taisuke
    Tanaka, Ryo
    Kaneko, Takahide
    Onishi, Masazumi
    Kuwatsuka, Yutaka
    Nagase, Kotaro
    Onuma, Takehiro
    Nomura, Motoo
    Umeda, Yoshiyasu
    Yamazaki, Naoya
    EUROPEAN JOURNAL OF CANCER, 2022, 176 : 78 - 87
12345